Audeara Posts $3.79m Revenue, $1.79m Loss in FY25 with Key International Orders

Revenue Growth and Operational Highlights

Audeara Limited has delivered a solid financial performance for the year ended 30 June 2025, reporting revenues of $3.79 million, an 18.9% increase over the previous year. This growth was primarily driven by a 25% uplift in Australian wholesale sales and a 13% increase in international markets, reflecting the company’s expanding global footprint.

Despite the top-line growth, Audeara recorded a net loss after tax of $1.79 million, slightly higher than the prior year’s $1.60 million loss. The company attributes this to continued investment in research and development, as well as strategic initiatives to scale its operations and product offerings.

Strategic Partnerships and International Expansion

A key highlight for FY25 was the strengthening of Audeara’s AUA Technology division, which focuses on licensing and manufacturing partnerships. The division generated stable revenues of $1.14 million and secured a significant purchase order valued at US$917,000 from Avedis Zildjian, a global music instrument brand. Post-year-end shipments of $672,598 are expected to contribute to FY26 revenue.

Further cementing its international ambitions, Audeara entered into a licensing agreement with Eastech Holding Limited, a Taiwan Stock Exchange-listed company, to bring its proprietary hearing health technology into the Chinese medical device market. This five-year agreement, executed after the reporting period, positions Audeara to tap into a market with an estimated 426 million people affected by hearing loss.

Product Innovation and Market Presence

Audeara expanded its product portfolio with three new launches, including the Audeara Buds, the company’s first in-ear device targeting the growing True Wireless audio segment. The launch of Auracast-enabled devices like the Audio Transceiver and Lapel Microphone further showcases Audeara’s commitment to accessible and inclusive hearing solutions.

The company’s international distribution network now spans 11 countries, including Australia, the USA, Taiwan, and several European markets, with pipeline opportunities in six additional countries. Audeara’s presence at key audiology and consumer electronics conferences, including CES 2025, has helped build strategic relationships and enhance brand recognition globally.

Financial Position and Going Concern

Audeara ended FY25 with cash and cash equivalents of $1.42 million, supported by a successful $1.35 million capital raise during the year. The company’s management has implemented cost optimization measures, resulting in improved operating cash flow compared to prior years.

However, the auditor’s report includes a material uncertainty related to the company’s ability to continue as a going concern, reflecting ongoing losses and negative operating cash flows. The directors remain confident that strategic partnerships, licensing revenues, and R&D incentives will support the company’s path to profitability.

Outlook

Looking ahead, Audeara is focused on fulfilling recent large orders, expanding its licensing agreements, and growing hardware sales in Australia and Europe. The company’s R&D efforts, including a new project with Ear Science Institute Australia to develop bone conduction hearing solutions, underscore its commitment to innovation and addressing unmet hearing health needs.

With a strengthened international presence and a scalable technology licensing model, Audeara aims to achieve breakeven in the near term while continuing to enhance shareholder value through sustainable growth.